Tuberculosis, Pulmonary Clinical Trial
Official title:
Primary Prophylaxis for Prevention of TB in Prison's Populations
The purpose of this study is to determine if the isoniazid is effective in the prevention of tuberculosis in a prison population, exposed to the high endemicity of the disease.
Despite being a known disease of mankind over 9000 years, tuberculosis (TB) is still a major
public health problem in developing countries, mainly due to so-called highly endemic sites,
such as prisons.
It is Infectious disease, with airborne transmission, TB can present both the active or
latent form. Despite the biological aspect of transmission, unhealthy environmental
conditions (room without direct sunlight, poor ventilation and overcrowded) and individual
factors (malnutrition, immunosuppression, use of alcohol and other drugs) have significant
influence on transferability and infectivity.
With the discovery of drugs active against Mycobacterium tuberculosis, it was observed a
reduction of disease incidence in the world. Despite this declining incidence, World Health
Organization (WHO) classifies TB as a public health problem due to the emergence of multidrug
strains or extensively resistant to treatment, added to the cases of latent TB reactivation,
observed with the advent of HIV/AIDS.
Studies show a direct relationship between the incidence of TB and the prison environment.
Nevertheless, the presence of prisons in one location increases the incidence of this
disease, indicating that there is an exchange of disease between the prison and the
community.
Currently, control of TB in the prison system is based on the tracking of individuals with
active TB and / or latent and, in their respective treatment. For the identification of
individuals with active disease, it is necessary the recognition of respiratory symptoms
(cough mainly) and sputum smear microscopy and sputum culture, and chest X-ray. As the search
of individuals with latent form, must be carried to the skin test with Purified Protein
Derived (PPD).
Most of the units of the Brazilian's prison system these diagnostic methods are not available
and hence the transport of individuals for their realization is necessary, generating an
additional cost, in most cases, unfeasible process execution.
With the completion of this study, it seek to determine the effectiveness of primary
prophylaxis in the prison population in order to gather new scientific evidence, to bring
affordable methods for the control of TB in prisons.
Despite advances in diagnosis and treatment TB, this is the third leading cause of death from
infectious diseases worldwide (Naghavi et al, 2015). In 2015, the WHO estimated incidence of
9.6 million new cases of TB in the world, with about 1.1 million deaths. For Brazil it was
estimated incidence of 44 cases per 100,000 (WHO, 2015). The incidence of TB has declined
about 2% per year, but this rate is not homogeneous in the global context.
Brazil occupies the 22nd place in the ranking of the WHO with an estimated annual rate of
83,310 cases of the disease (Zumla et al, 2015). In the past seven years, it is estimated
that the incidence declined only 0.7% (per year). A key factor in this slow progress in TB
control in Brazil, and other emerging countries is the existence of high-risk subpopulations,
including slums and prisons, which act as reservoirs and amplifiers for the transmission of
the disease (Basu; Stückler; Mckee 2011; Dowdy et al, 2012). A recent systematic review
showed that the average incidence of TB in the prison population can be up to 23 times that
recorded in the general population (Baussano et al, 2010).
With the fourth largest prison populations in the world, is observed in Brazil, the increased
incidence of TB among prisoners in the last seven years. Although prisoners represent only
0.3% of the population, the increase in the prison population over this period resulted in
almost doubling the proportion of all TB cases that occur among prisoners (4.1% in 2007, 8,
1% in 2013).
The arrests are in an ideal environment for the spread of TB, since they show individuals
users of tobacco and alcohol in high doses, in addition to drug abuse in overcrowded cells
with poor ventilation and with limited access to care health and diagnosis of TB. Currently,
the Ministry of Health recommends active search for TB at the entrance to the prison and once
a year by chest X-ray. Due to the cost and logistics, most prisons do not adhere to this
recommendation. There is also a clear recommendation not to use the tuberculin skin test or
perform the treatment for latent tuberculosis. If the procedures for active case detection
and / or prophylactic treatment would impact the high transmission in prisons is a question
that still remains open (Al-Darraji; Kamarulzamn; Altice, 2012).
The concentration of cases of TB in prisons can represent both an obstacle and an opportunity
to control the disease, depending on the effectiveness of interventions in these
environments.
Preliminary studies show high annual rate of TB infection (26%) among the prison population
of 12 penitentiaries of Mato Grosso do Sul. Besides the large burden of disease in this
population is significant dispersion of the TB prison to the community (Sacchi et al, 2015).
Cross-sectional studies show high yield annual screening for TB, however, the effectiveness
of this measure combined with other interventions remains unclear (Ferreira et al, 1996;
Fournet et al, 2006; Lemos et al, 2014; Vieira et al, 2010; Sanches et al, 2013; Walnut;
Abrahão; Galesi, 2012; Kuhleis et al, 2012; Estevan; Oliveira; Croda, 2013). Due to the
combination of high force of infection in prisons and short prison term, primary prophylaxis
may be an effective intervention. This new approach has never been evaluated in the context
of prisons in low and middle income countries; to assess the impact of program strategies for
TB screening and prophylaxis, longitudinal data will be essential. Given the infrastructure
that was created for long-term prospective studies in Brazil, there is an excellent
opportunity to close the critical knowledge gaps that have been barriers to effective
implementation of TB control in high transmission prisons.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06084715 -
The INSTITUT Study
|
||
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Withdrawn |
NCT03862248 -
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
|
Phase 3 | |
Completed |
NCT03271567 -
Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Active, not recruiting |
NCT04919239 -
Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)
|
Phase 2 | |
Active, not recruiting |
NCT03251196 -
TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB
|
||
Recruiting |
NCT05926466 -
BTZ-043 Dose Evaluation in Combination and Selection
|
Phase 2 | |
Recruiting |
NCT04752592 -
Evaluation of a Rapid Point-of-Care Serological Triage Test for Active TB
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Not yet recruiting |
NCT04968886 -
TuBerculosis Viability Interregional Study and Agreement on Biological Tests
|
||
Not yet recruiting |
NCT04485156 -
Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
|
Phase 3 | |
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT01364324 -
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT05899400 -
A Study to Validate and Improve an Automated Image Analysis Algorithm to Detect Tuberculosis in Sputum Smear Slides
|
||
Completed |
NCT04938596 -
Airborne Preventive Measures to Reduce New TB Infections in Household Contacts
|
N/A | |
Recruiting |
NCT05455112 -
Safety and Efficacy of RUTI® With the Standard of Treatment for Tuberculosis
|
Phase 2 | |
Completed |
NCT03044158 -
GeneXpert Performance Evaluation for Linkage to Tuberculosis Care
|
N/A | |
Withdrawn |
NCT03941496 -
Azacytidine During Anti-tuberculosis Therapy
|
Phase 1/Phase 2 |